Issue

Vol. 66 No. 6: Issue 6

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway

https://doi.org/10.14715/cmb/2020.66.6.15
Ruilan Yuan
Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030012, China
Jin Chang
Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030012, China
Jianxia He
Department of Hematology, Shanxi Provincial People's Hospital, Taiyuan, 030012, China

Corresponding Author(s) : Jin Chang

gordon5286@yandex.com

Cellular and Molecular Biology, Vol. 66 No. 6: Issue 6

Abstract

This study aimed to investigate the effects of Twist1 on the drug resistance of chronic myeloid leukemia (CML) cells through the PI3K/AKT signaling pathway. K562 and KCL-22 cells were modeled for imatinib resistance, so as to analyze the effects of inhibiting Twist1 and the pathway on the therapeutic effect of imatinib on imatinib-resistant CML cells, and to find the mechanism of action of Twist1 on affecting the resistance. After the CML cells were successfully resistant to imatinib, Twist1 expression increased again in the cells and the PI3K/AKT signaling pathway was further activated. After the silence of the Twist1 expression, the imatinib-resistant CML cells were more sensitive to imatinib, and the PI3K/AKT signaling pathway was inhibited, and the expression level of p-AKT protein significantly reduced. According to further experiments, imatinib enhanced its inhibitory effect on the growth of the imatinib-resistant CML cells after the activation of the pathway was inhibited by an LY3023414 inhibitor. In conclusion, Twist1 and the PI3K/AKT signaling pathway are over-activated during the formation of the CML cells resistant to imatinib. The silence of Twist1 can reverse the resistance through the pathway.

Keywords

Twist1 PI3K/AKT chronic myeloid leukemia drug resistance
Yuan, R., Chang, J., & He, J. (2020). Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway. Cellular and Molecular Biology, 66(6), 81–85. https://doi.org/10.14715/cmb/2020.66.6.15
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Qin L, Deng HY, Chen SJ, Wei W. Relationship between cigarette smoking and risk of chronic myeloid leukaemia: a meta-analysis of epidemiological studies. Hematol 2017; 22(4):193-200.
  2. Rohrbacher M, Hasford J. Epidemiology and Etiology of Chronic Myeloid Leukemia. Neoplast Dis Blood 2018; (pp. 9-17). Springer, Cham.
  3. Hoffmann VS, Baccarani M, Hasford J, Lindörfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leuk 2015; 29(6):1336-43.
  4. Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 2015; 94(2): 241-247.
  5. Huang WK, Akçakaya P, Gangaev A, Lee L, Zeljic K, Hajeri P, Berglund E, Ghaderi M, í…hlén J, Bränström R, Larsson C. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors. Exp Cell Res 2018; 371(1):287-96.
  6. Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation. Cancer Res 2016; 76(6):1451-62.
  7. Xu Y, Qin L, Sun T, Wu H, He T, Yang Z, Mo Q, Liao L, Xu J. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene 2017; 36(8):1157-66.
  8. Zhu X, Shen H, Yin X, Long L, Xie C, Liu Y, Hui L, Lin X, Fang Y, Cao Y, Xu Y. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene 2016; 35(3):323-32.
  9. Liu YR, Liang L, Zhao JM, Zhang Y, Zhang M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, Chen S. Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transporters. Oncotarget 2017; 8(32):52901.
  10. Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, Rudin CM. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene 2019; 38(5):656-70.
  11. Heidari N, Vosoughi T, Mohammadi Asl J, Saki Malehi A, Saki N. How is the relationship between TWIST-1 and BCR-ABL1 gene expressions in chronic myeloid leukaemia patients? Biomark 2018; 23(3):271-6.
  12. Vara Jí, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30(2):193-204.
  13. Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med 2016; 67:11-28.
  14. Baek SH, Ko JH, Lee JH, Kim C, Lee H, Nam D, Lee J, Lee SG, Yang WM, Um JY, Sethi G. Ginkgolic acid inhibits invasion and migration and tgf"β"induced emt of lung cancer cells through pi3k/akt/mtor inactivation. J Cell Physiol 2017; 232(2):346-54.
  15. Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 2017; 14(10):611.
  16. Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev 2016; 35(4):515-24.
  17. Mikheev AM, Mikheeva SA, Severs LJ, Funk CC, Huang L, McFaline"Figueroa JL, Schwensen J, Trapnell C, Price ND, Wong S, Rostomily RC. Targeting TWIST 1 through loss of function inhibits tumorigenicity of human glioblastoma. Mol Oncol 2018; 12(7):1188-202.
  18. Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, Mahon FX, Dumontet C, Puisieux A, Nicolini FE, Maguer-Satta V. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood, J Am Soc Hematol 2011; 117(5):1673-6.
  19. Lu Y, Li Y, Chai X, Kang Q, Zhao P, Xiong J, Wang J. Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia. Gene 2017; 607:41-6.
  20. Roberts CM, Tran MA, Pitruzzello MC, Wen W, Loeza J, Dellinger TH, Mor G, Glackin CA. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling. Sci Rep 2016; 6:37652.
  21. Yang J, Xing H, Hong L, Lu D, Li B, Tang J, Min J. STAT3-mediated Twist1 upregulation contributes to epithelial-mesenchymal transition in cisplatin resistant ovarian cancer. Int J Clin Exp Med 2018; 11(7):6749-57.
  22. Wu YH, Huang YF, Chang TH, Chou CY. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF"κB"mediated IKKβ expression. Int J Cancer 2017; 141(11):2305-17.
  23. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Mod Genet J 2020; 15(2): 75-92.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 826 Download : 465